Longitude beats 'brutal' conditions as new life science fund exceeds target
This article was originally published in Scrip
After reporting in September that it raised $331.6 million of a $375 million venture capital fund, Menlo Park, California-based Longitude Capital announced on 10 October that it closed Longitude Venture Partners II with $385 million to invest in drug development and medical technology.
You may also be interested in...
Gene editing is all the rage in biotechnology these days, but Caribou Biosciences Inc. has taken a different path than its CRISPR peers by diversifying beyond therapeutics to agriculture, industrial and applied research. The company also has taken a different financing path – recently closing a $30m Series B venture capital round instead of pursuing an initial public offering.
CAR-T therapy-associated T-cell malignancies that the US FDA is investigating could make the treatments less attractive in autoimmune diseases than in oncology, but patients in both settings already accept some cancer risk with other available medicines.
SpringWorks’ gamma secretase inhibitor will be available soon for adults at any stage of treatment for desmoid tumors with a list price of $29,000 for a 30-day supply.